Tier 2 — strong

Comparison of quercetin pharmacokinetics following oral supplementation in humans

Diksha Kaushik, Kevin O'Fallon, Priscilla M Clarkson, C Patrick Dunne, Karen R Conca, Bozena Michniak-Kohn
Journal of food science 2012 77(11):H231

Bibliography

PubMed
PMID 23094941
DOI
10.1111/j.1750-3841.2012.02934.x
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignHuman parallel-group formulation pharmacokinetic comparison
ModelHuman intervention research
Sample18 healthy volunteers; 6 per formulation
InterventionQuercetin 500 mg as a drink, bar, or chew
DurationSingle dose; 32-hour blood sampling
EndpointsExposure and pharmacokinetics

What the study showed, in plain terms

Published in 2012, this source examined forms, absorption and food sources. Design: Human parallel-group formulation pharmacokinetic comparison. Sample/model: 18 healthy volunteers; 6 per formulation. The exposure or intervention was Quercetin 500 mg as a drink, bar, or chew. Follow-up or treatment period: Single dose; 32-hour blood sampling.

Peak concentrations differed numerically across carriers, but absorption differences were not statistically significant because of substantial variation.

Small groups and high variability prevent a claim that one carrier was proven superior. No clinical health outcome was measured.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Forms: Dihydrate, Phytosome, Liposomal and Glycosides. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Peak concentrations differed numerically across carriers, but absorption differences were not statistically significant because of substantial variation.
  • The recorded outcome domains were Exposure and pharmacokinetics.
  • The result applies to the tested exposure: Quercetin 500 mg as a drink, bar, or chew; Single dose; 32-hour blood sampling.

What this study can and cannot tell us

  • Small groups and high variability prevent a claim that one carrier was proven superior. No clinical health outcome was measured.
  • A change in blood exposure or a metabolic marker is not a demonstrated improvement in symptoms, disease events or lifespan. The tested formulation and co-administered medicines matter.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Improving quercetin bioavailability: A systematic review and meta-analysis of human intervention studies
Lu Liu et al. · Food chemistry · 2025
Tier 2
Microbiological and Pharmacokinetic Aspects of a Water-Soluble Quercetin 3-O-rutinoside, EubioQuercetin: A Direct Comparison With Quercetin in In Vitro and Human Clinical Studies
Naoto Yamaguchi et al. · Journal of food science · 2025
Tier 2
Comparative Pharmacokinetics and Safety of a Micellar Chrysin-Quercetin-Rutin Formulation: A Randomized Crossover Trial
Afoke Ibi et al. · Antioxidants (Basel, Switzerland) · 2025
Tier 2
Enhanced Bioavailability and Pharmacokinetics of a Natural Self-Emulsifying Reversible Hybrid-Hydrogel System of Quercetin: A Randomized Double-Blinded Comparative Crossover Study
Ashil Joseph et al. · ACS omega · 2022

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology